Aprea Therapeutics appoints Gabriela Gruia, M.D. to board; grants 12,500-share option

Aprea Therapeutics, Inc.

Board expanded from 8 to 9 directors; Dr. Gruia appointed as Class II director effective May 5, 2023.
Option to purchase 12,500 shares at $3.86 (closing price on grant date) fully vesting in one year.
Dr. Gruia brings 25+ years in oncology drug development; former SVP at Novartis Oncology leading 12 NME approvals.
No familial or transaction relationships requiring disclosure; serves until 2024 annual meeting or resignation.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gabriela Gruia, M.D.

Class II director

APRE · Aprea Therapeutics, Inc.

Effective: 2023-05-05
Filed: May 8, 2023, 7:59 PM ET

On May 5, 2023, the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Gabriela Gruia, M.D., as a Class II director and new member of the Board to fill the vacancy on the Board, effective immediately, to serve until the Company’s 2024 annual meeting of stockholders or until her earlier resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gabriela Gruia, M.D. was appointed as Class II director at Aprea Therapeutics, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On May 5, 2023, the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Gabriela Gruia, M.D., as a Class II director and new member of the Board to fill the vacancy on the Board, effective immediately, to serve until the Company’s 2024 annual meeting of stockholders or until her earlier resignation or removal.

View on SEC.gov

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008389

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.